PTIE News Alert Pain Therapeutics (PTIE) 1.86 12/13/2014 06:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pain Therapeutics (PTIE) 1.86 $PTIE

Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST

MNK: 94.72 (-0.36), JNJ: 104.43 (-2.29), ENDP: 68.77 (-2.45), ACT: 259.00 (-4.00), DRRX: 0.87 (+0.03), NVS: 93.52 (-0.82), PTIE: 1.86 (+0.08)

Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), PRAN: 1.86 (-0.05), PTIE: 1.86 (+0.08), CUR: 2.58 (-0.09)

Painkiller Remoxy (Oxycodone) May Still See An NDA Refiling By Mid-2015
Clinically Sound Investor - at Seeking Alpha - Tue Nov 25, 10:24AM CST

PTIE: 1.86 (+0.08)

President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit
PRWeb - Tue Nov 11, 9:06AM CST
President and CEO of Proove Biosciences, Brian Meshkin, spoke at the 8th Annual Pain Therapeutics Summit on the Emerging Role of Genetics in Pain Management. The Annual Pain and Migraine Therapeutics Summit is the premier conference covering the field of pain research and emerging therapeutic methods. The event attracts leaders from the pharmaceutical, biotech, device and medical communities to learn about the cutting-edge advances in various treatments of pain. Mr. Meshkin was among a panel of speakers including key industry leaders and academic researchers concerning the latest drug discovery science and analysis of pain therapies.
PTIE: 1.86 (+0.08)

Pain Therapeutics lowers earnings 250% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:14PM CST

PTIE: 1.86 (+0.08)

Pain Therapeutics - Drugs, Markets and Companies
PR Newswire - Mon Nov 03, 7:02AM CST
Research and Markets has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 1.86 (+0.08)

Pain Therapeutics' (PTIE) CEO Remi Barbier on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:37PM CDT

PTIE: 1.86 (+0.08)

Pain Therapeutics Reports Q3 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:51PM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today reported financial results for Q3 2014. Net loss in Q3 2014 was $3.5 million, or $0.08 per share, compared to a net loss in Q3 2013 of $0.8 million, or $0.02 per share. Net cash used in Q3 2014 was $1.7 million. We continue to believe net cash usage for full calendar year 2014 may be about $12 million. At September 30, 2014, cash and investments were $43.2 million.
PTIE: 1.86 (+0.08)

Pain Therapeutics EPS of -$0.08
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:50PM CDT

PTIE: 1.86 (+0.08)

Nasdaq stocks posting largest volume increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LAYN: 8.22 (+0.46), TRNX: 26.39 (-0.14), DRRX: 0.87 (+0.03), CEMI: 4.30 (+0.03), PBCP: 10.50 (+0.10), PTIE: 1.86 (+0.08), AMDA: 0.69 (-0.01)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.31 (-0.14), KSS: 57.27 (+0.37), MU: 34.00 (-1.19), PFE: 30.95 (-0.70), HAL: 37.93 (-0.30), AMGN: 164.53 (-1.55), NQ: 5.35 (-0.09), RGC: 20.87 (+0.02), MS: 36.25 (-1.15), MSG: 72.52 (-0.13), NVAX: 5.76 (-0.17), CQB: 14.46 (+0.01), SRPT: 13.97 (-0.33), RCPT: 120.08 (-1.38), TWTR: 37.10 (+0.40), PTIE: 1.86 (+0.08)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:49AM CDT

GFA: 1.59 (-0.04), FST: 0.36 (-0.04), ZAZA: 1.46 (-0.13), EBR: 2.03 (+0.01), VTAE: 22.01 (+0.30), XGTI: 1.02 (-0.04), VBIV: 3.48 (-0.03), DRRX: 0.87 (+0.03), CEMI: 4.30 (+0.03), PBR: 7.11 (-0.31), CBDE: 0.90 (+0.06), OMEX: 1.00 (-0.02), LAYN: 8.22 (+0.46), SRPT: 13.97 (-0.33), CNIT: 4.30 (+0.09), AKBA: 11.33 (+0.25), CTP: 14.76 (+0.31), VPCO: 1.31 (+0.04), PTIE: 1.86 (+0.08)

Pfizer (PFE) Stock Falls After Dropping Pain Drug
at The Street - Mon Oct 27, 10:37AM CDT
Shares of Pfizer (PFE) are down after the pharmaceutical company decided to discontinue its agreement to develop and commercialize the drug Remoxy, an oral formulation of oxycodone.
PFE: 30.95 (-0.70), PTIE: 1.86 (+0.08)

Durect and Pain Therapeutics plunge after Pfizer backs out of Remoxy development
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:26AM CDT

PFE: 30.95 (-0.70), DRRX: 0.87 (+0.03), PTIE: 1.86 (+0.08)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:13AM CDT

GFA: 1.59 (-0.04), PBR.A: 7.57 (-0.41), VNDA: 12.72 (-0.17), ELP: 12.91 (+0.41), DRRX: 0.87 (+0.03), NBG: 1.79 (-0.01), NQ: 5.35 (-0.09), CEMI: 4.30 (+0.03), VIV: 17.58 (-0.54), PBR: 7.11 (-0.31), BBD: 12.83 (-0.61), NVAX: 5.76 (-0.17), SRPT: 13.97 (-0.33), GOL: 5.43 (-0.24), DGLY: 15.55 (+1.34), ITUB: 12.62 (-0.61), GPRO: 60.52 (+0.47), ERJ: 35.23 (-0.99), EBR: 2.03 (+0.01), CBD: 37.12 (-0.62), CIG: 4.90 (+0.03), CPL: 13.77 (-0.29), RNA: 18.76 (-0.21), VALE: 7.19 (-0.07), SBS: 6.54 (-0.03), AEZS: 0.60 (+0.03), PAY: 33.01 (-1.47), PTIE: 1.86 (+0.08)

DURECT Provides Update on REMOXY® and POSIDUR(TM) Programs
PR Newswire - Mon Oct 27, 7:05AM CDT
DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY® (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
PFE: 30.95 (-0.70), DRRX: 0.87 (+0.03), PTIE: 1.86 (+0.08)

Pfizer to Discontinue Agreement on REMOXY(TM) (oxycodone) Extended-Release Capsules CII
Business Wire - Mon Oct 27, 7:02AM CDT
Pfizer Inc. (NYSE FE) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY(TM) (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc.
PFE: 30.95 (-0.70), PTIE: 1.86 (+0.08)

Pain Therapeutics to Regain Full Rights to REMOXY(R)
GlobeNewswire - Mon Oct 27, 7:00AM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today reported it believes it will regain full development and commercial rights to REMOXY from Pfizer, Inc. On Friday, October 24, Pfizer hosted a conference call with us during aftermarket hours to inform us of their intention to terminate development of REMOXY. Actual termination will become effective six months from today, pursuant to the terms of a Collaboration Agreement.
PFE: 30.95 (-0.70), PTIE: 1.86 (+0.08)

Pain Therapeutics reports October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 6:15PM CDT

PTIE: 1.86 (+0.08)

Pain Therapeutics to Host Conference Call to Discuss Q3 2014 Financial Results
GlobeNewswire - Thu Oct 23, 5:00PM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) will host a conference call on Thursday, October 30th at 3:30 p.m. Central Time/4:30 p.m. Eastern Time to discuss Q3 2014 financial results and provide an update on the Company.
PTIE: 1.86 (+0.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 244

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 129

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 63

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 50 Years: Mobil 1™ and Autodromo Partner Up

Updated Category News Views 237

Mobil 1™ Celebrates Milestone with Unique Autodromo Collaboration In a remarkable celebration of its 50-year anniversary, Mobil 1™, a pioneer in synthetic motor oil, has teamed up with Autodromo, renowned for its driving-inspired watches. This collaboration introduces the Mobil 1 Edition Monoposto, a limited-edition timepiece, showcasing their shared commitment to...

Continue Reading
diaMentis Introduces Innovative Breakthrough in Mental Health Diagnosis

Updated Category News Views 256

Advancements in Mental Health Diagnosis diaMentis, known for its forward-thinking diagnostic support technology, is making waves in the mental health sector by revealing groundbreaking results that enhance the diagnosis of mental illnesses. These findings not only signify a major breakthrough, but also represent a turning point for the company, enhancing its reputation in...

Continue Reading
CleanSpark's Impressive Growth: Achieving 30 EH/s in Hashrate

Updated Category News Views 77

CleanSpark's Breakthrough in Hashrate Efficiency CleanSpark Inc. (NASDAQ: CLSK), renowned as America's leading bitcoin miner, recently reached an operational hashrate of 30 EH/s (exahashes per second). This significant milestone reflects the company's remarkable growth and innovation in the competitive bitcoin mining industry. Transformative Growth through Strategic...

Continue Reading
Baidu's Bold Move: Aiming to Compete in Global Robotaxi Market

Updated Category News Views 108

Baidu's Ambitious Expansion Plans in Robotaxi Services Baidu Inc. is reportedly considering an exciting venture to extend its renowned robotaxi service, Apollo Go, into international markets. This bold decision follows a significant transition within the company as its CFO, Rong Luo, assumes a new role. Such developments signal Baidu's commitment to unlocking new avenues...

Continue Reading
Airship AI Secures Major Federal Contracts Amid Growing Demand

Updated Category News Views 198

Airship AI Achieves Significant Federal Contracts REDMOND, Wash. — Airship AI Holdings, Inc. (NASDAQ: AISP) is celebrating a remarkable accomplishment in the realm of public safety and security. The company has recently secured 16 individual contracts from various federal law enforcement agencies, highlighting the ongoing relevance and necessity of AI technologies in...

Continue Reading